Clin Colon Rectal Surg 2018; 31(05): 288-294
DOI: 10.1055/s-0038-1642052
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Appendiceal Tumors and Colorectal Adenocarcinomas

Michael Kuncewitch
1   Department of Surgery, Wake Forest School of Medicine, Winston-Salem, North Carolina
,
Edward A. Levine
1   Department of Surgery, Wake Forest School of Medicine, Winston-Salem, North Carolina
,
Perry Shen
1   Department of Surgery, Wake Forest School of Medicine, Winston-Salem, North Carolina
,
Konstantinos I. Votanopoulos
1   Department of Surgery, Wake Forest School of Medicine, Winston-Salem, North Carolina
› Author Affiliations
Further Information

Publication History

Publication Date:
04 September 2018 (online)

Abstract

Peritoneal surface disease (PSD) has historically been used interchangeably with the term peritoneal carcinomatosis (PC) and has a dismal natural history. A variety of malignant pathologies, including colorectal and appendiceal primary tumors, can disseminate throughout the peritoneal cavity, leading to bowel obstruction and death. In general, peritoneal spread from high-grade appendiceal and colorectal primaries has the potential of hepatic and distant spread and best classified as PC. Low-grade appendiceal tumors are better categorized as PSD, due to low cellularity, high mucin production, and lack of potential spread outside the peritoneal cavity. Growing international experience with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) over the past 30 years has presented a therapeutic option to patients with PSD from colorectal and appendiceal tumors that can provide significant disease control, as well as potential for previously unattainable long-term survival. The proliferation of HIPEC centers and ongoing prospective trials are helping to standardize HIPEC techniques and patient selection.

 
  • References

  • 1 Jayne D. Molecular biology of peritoneal carcinomatosis. Cancer Treat Res 2007; 134: 21-33
  • 2 Sugarbaker PH. Peritoneum as the first-line of defense in carcinomatosis. J Surg Oncol 2007; 95 (02) 93-96
  • 3 Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg 2006; 243 (02) 212-222
  • 4 Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002; 89 (12) 1545-1550
  • 5 Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg 2012; 99 (05) 699-705
  • 6 Shapiro JF, Chase JL, Wolff RA. , et al. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. Cancer 2010; 116 (02) 316-322
  • 7 American Cancer Society. Cancer Facts and Figures 2017. Atlanta, GA: American Cancer Society; 2017
  • 8 Sadeghi B, Arvieux C, Glehen O. , et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000; 88 (02) 358-363
  • 9 Paul Olson TJ, Pinkerton C, Brasel KJ, Schwarze ML. Palliative surgery for malignant bowel obstruction from carcinomatosis: a systematic review. JAMA Surg 2014; 149 (04) 383-392
  • 10 Shariat-Madar B, Jayakrishnan TT, Gamblin TC, Turaga KK. Surgical management of bowel obstruction in patients with peritoneal carcinomatosis. J Surg Oncol 2014; 110 (06) 666-669
  • 11 Franko J, Shi Q, Goldman CD. , et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 2012; 30 (03) 263-267
  • 12 Sugarbaker PH. Patient selection and treatment of peritoneal carcinomatosis from colorectal and appendiceal cancer. World J Surg 1995; 19 (02) 235-240
  • 13 Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995; 221 (01) 29-42
  • 14 Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 1998; 14 (03) 254-261
  • 15 Verwaal VJ, van Ruth S, de Bree E. , et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21 (20) 3737-3743
  • 16 Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008; 15 (09) 2426-2432
  • 17 Elias D, Gilly F, Boutitie F. , et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010; 28 (01) 63-68
  • 18 Glehen O, Kwiatkowski F, Sugarbaker PH. , et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004; 22 (16) 3284-3292
  • 19 Turaga K, Levine E, Barone R. , et al. Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol 2014; 21 (05) 1501-1505
  • 20 Chouliaras K, Levine EA, Fino N, Shen P, Votanopoulos KI. Prognostic factors and significance of gastrointestinal leak after cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 2017; 24 (04) 890-897
  • 21 Kwakman R, Schrama AM, van Olmen JP. , et al. Clinicopathological parameters in patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases: a meta-analysis. Ann Surg 2016; 263 (06) 1102-1111
  • 22 Trivedi AN, Levine EA, Mishra G. Adenocarcinoma of the appendix is rarely detected by colonoscopy. J Gastrointest Surg 2009; 13 (04) 668-675
  • 23 Winer J, Zenati M, Ramalingam L. , et al. Impact of aggressive histology and location of primary tumor on the efficacy of surgical therapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2014; 21 (05) 1456-1462
  • 24 van Oudheusden TR, Braam HJ, Nienhuijs SW. , et al. Poor outcome after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis with signet ring cell histology. J Surg Oncol 2015; 111 (02) 237-242
  • 25 Simkens GA, Razenberg LG, Lemmens VE, Rutten HJ, Creemers GJ, de Hingh IH. Histological subtype and systemic metastases strongly influence treatment and survival in patients with synchronous colorectal peritoneal metastases. Eur J Surg Oncol 2016; 42 (06) 794-800
  • 26 Randle RW, Votanopoulos KI, Levine EA, Shen P, Stewart JH. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Dissemination of Colorectal Cancer. Operative Techniques in Colon and Rectal Surgery. Philadelphia: Lippincott Williams and Wilkins; 2015
  • 27 Patel CM, Sahdev A, Reznek RHCT. CT, MRI and PET imaging in peritoneal malignancy. Cancer Imaging 2011; 11: 123-139
  • 28 Rohani P, Scotti SD, Shen P. , et al. Use of FDG-PET imaging for patients with disseminated cancer of the appendix. Am Surg 2010; 76 (12) 1338-1344
  • 29 Taflampas P, Dayal S, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ. Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal pseudomyxoma peritonei: analysis of 519 patients. Eur J Surg Oncol 2014; 40 (05) 515-520
  • 30 Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996; 82: 359-374
  • 31 Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 1999; 43 (Suppl): S15-S25
  • 32 Faron M, Macovei R, Goéré D, Honoré C, Benhaim L, Elias D. Linear relationship of peritoneal cancer index and survival in patients with peritoneal metastases from colorectal cancer. Ann Surg Oncol 2016; 23 (01) 114-119
  • 33 Klaver CE, Groenen H, Morton DG, Laurberg S, Bemelman WA, Tanis PJ. ; research committee of the European Society of Coloproctology. Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelines. Colorectal Dis 2017; 19 (03) 224-236
  • 34 Chua TC, Moran BJ, Sugarbaker PH. , et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 2012; 30 (20) 2449-2456
  • 35 Levine EA, Stewart IV JH, Russell GB, Geisinger KR, Loggie BL, Shen P. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures. J Am Coll Surg 2007; 204 (05) 943-953 , discussion 953–955
  • 36 Levine EA, Stewart IV JH, Shen P, Russell GB, Loggie BL, Votanopoulos KI. Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. J Am Coll Surg 2014; 218 (04) 573-585
  • 37 Shen P, Levine EA, Hall J. , et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg 2003; 138 (01) 26-33
  • 38 Spiliotis J, Vaxevanidou A, Sergouniotis F, Lambropoulou E, Datsis A, Christopoulou A. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study. J BUON 2011; 16 (01) 74-79
  • 39 Van Sweringen HL, Hanseman DJ, Ahmad SA, Edwards MJ, Sussman JJ. Predictors of survival in patients with high-grade peritoneal metastases undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Surgery 2012; 152 (04) 617-624 , discussion 624–625
  • 40 Leung V, Huo YR, Liauw W, Morris DL. Oxaliplatin versus mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis. Eur J Surg Oncol 2017; 43 (01) 144-149
  • 41 Lambert LA. Looking up: recent advances in understanding and treating peritoneal carcinomatosis. CA Cancer J Clin 2015; 65 (04) 284-298
  • 42 Allard MA, Adam R, Ruiz A. , et al. Is unexpected peritoneal carcinomatosis still a contraindication for resection of colorectal liver metastases? Combined resection of colorectal liver metastases with peritoneal deposits discovered intra-operatively. Eur J Surg Oncol 2013; 39 (09) 981-987
  • 43 Randle RW, Doud AN, Levine EA. , et al. Peritoneal surface disease with synchronous hepatic involvement treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 2015; 22 (05) 1634-1638
  • 44 Votanopoulos KI, Swett K, Blackham AU. , et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from rectal cancer. Ann Surg Oncol 2013; 20 (04) 1088-1092
  • 45 Randle RW, Swett KR, Swords DS. , et al. Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. Ann Surg Oncol 2014; 21 (05) 1474-1479
  • 46 Newton AD, Bartlett EK, Karakousis GC. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality. J Gastrointest Oncol 2016; 7 (01) 99-111
  • 47 Doud AN, Levine EA, Fino NF, Stewart JH, Shen P, Votanopoulos KI. Stoma creation and reversal after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2016; 23 (02) 503-510
  • 48 de Cuba EM, Verwaal VJ, de Hingh IH. , et al. Morbidity associated with colostomy reversal after cytoreductive surgery and HIPEC. Ann Surg Oncol 2014; 21 (03) 883-890
  • 49 Collins DC. 71,000 Human appendix specimens. A final report, summarizing forty years' study. Am J Proctol 1963; 14: 265-281
  • 50 Levine EA, Blazer III DG, Kim MK. , et al. Gene expression profiling of peritoneal metastases from appendiceal and colon cancer demonstrates unique biologic signatures and predicts patient outcomes. J Am Coll Surg 2012; 214 (04) 599-606 , discussion 606–607
  • 51 Bradley RF, Stewart IV JH, Russell GB, Levine EA, Geisinger KR. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol 2006; 30 (05) 551-559
  • 52 Stewart IV JH, Shen P, Russell GB. , et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol 2006; 13 (05) 624-634
  • 53 Ross A, Sardi A, Nieroda C, Merriman B, Gushchin V. Clinical utility of elevated tumor markers in patients with disseminated appendiceal malignancies treated by cytoreductive surgery and HIPEC. Eur J Surg Oncol 2010; 36 (08) 772-776
  • 54 Votanopoulos KI, Shen P, Stewart IV JH, Levine EA. Current status and future directions in appendiceal cancer with peritoneal dissemination. Surg Oncol Clin N Am 2012; 21 (04) 599-609
  • 55 Votanopoulos KI, Russell G, Randle RW, Shen P, Stewart JH, Levine EA. Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases. Ann Surg Oncol 2015; 22 (04) 1274-1279
  • 56 Dodson RM, McQuellon RP, Mogal HD. , et al. Quality-of-life evaluation after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2016; 23 (Suppl. 05) 772-783